| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CGA |
| Entrez GeneID | 1113 |
| clone | 5H10B12 |
| WB Predicted band size | 50kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CHGA (AA: 278-457) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
1. **"Chromogranin A as a neuroendocrine tumor marker"**
- **作者**: Lloyd RV, Wilson BS
- **摘要**: 综述了CHGA作为神经内分泌肿瘤特异性标志物的作用，强调其抗体在免疫组化诊断中的应用，并讨论了其在血清检测中的潜在价值。
2. **"Chromogranin A and chromogranin B in non-neuroendocrine tumours"**
- **作者**: Portela-Gomes GM, Stridsberg M
- **摘要**: 通过多种CHGA抗体对比研究，揭示了不同抗体对神经内分泌与非神经内分泌肿瘤的识别特异性，指出抗体选择对诊断准确性的影响。
3. **"Diagnostic utility of chromogranin A in neuroendocrine lung tumors"**
- **作者**: Pelosi G, Fraggetta F
- **摘要**: 评估CHGA抗体在肺神经内分泌肿瘤中的敏感性，发现其在典型类癌中高表达，而在低分化肿瘤中可能缺失，强调结合其他标志物的必要性。
4. **"Standardization of chromogranin A antibody testing"**
- **作者**: D’amico MA, Ghinelli C
- **摘要**: 提出CHGA抗体在实验室间存在检测差异，建议通过统一抗原修复方法和验证流程提高结果一致性，以优化临床诊断可靠性。
Chromogranin A (CHGA) is a 48 kDa acidic protein belonging to the granin family, primarily stored in secretory granules of neuroendocrine cells, including neurons, endocrine cells, and neuroendocrine tumors. It plays a critical role in regulating hormone/neurotransmitter storage, secretion, and granule formation. CHGA antibodies are essential tools in research and diagnostics for detecting CHGA expression, serving as a hallmark marker for neuroendocrine differentiation.
In clinical pathology, CHGA antibodies are widely used in immunohistochemistry (IHC) to identify neuroendocrine tumors (e.g., pheochromocytoma, neuroblastoma, carcinoids) and distinguish them from non-neuroendocrine neoplasms. Elevated CHGA levels in serum or tissue correlate with tumor burden, aiding in disease monitoring. Beyond oncology, CHGA is implicated in cardiovascular and metabolic disorders, as it is co-released with catecholamines and processed into bioactive peptides (e.g., vasostatin, pancreastatin) influencing blood pressure, glucose metabolism, and inflammation.
Antibodies targeting specific CHGA epitopes enable studies on its processing, trafficking, and interaction with secretory pathways. However, interpretation requires caution due to variable expression across tissues and potential cross-reactivity with structurally similar granins. Overall, CHGA antibodies remain pivotal in elucidating neuroendocrine biology and improving diagnostic accuracy.
×
